赵玉苹
ZHAO Yuping

• 1:北京市通州区次渠卫生院

摘要(Abstract)：

目的:探讨缺血性脑卒中患者发病前抗血小板药物的应用对患者病情严重程度及疾病转归的影响。方法:98例缺血性脑卒中患者根据发病前是否应用抗血小板药物分为观察组与对照组,入院后均给予吸氧、降颅压、抗血小板等常规治疗,对比两组患者入院时美国国立卫生研究院卒中量表(NIHSS)评分、颅脑卒中面积、治疗1周时颅内出血发生率、症状性颅内出血发生率、死亡率,并于发病第90天时采用改良Rankin量表评估患者预后。结果:两组患者入院时NIHSS评分及颅脑CT卒中面积比较差异均无统计学意义(P>0.05);治疗1周时两组患者颅内出血发生率、症状性颅内出血发生率以及死亡率比较,差异均无统计学意义(P>0.05);发病第90天两组患者预后良好率及预后不良率比较差异无统计学意义(P>0.05)。结论:缺血性脑卒中患者发病前应用抗血小板药物并未对疾病的严重程度及转归造成明显影响。
Objective: To discuss the influence of premorbid application of antiplatelet drugs on severity and prognosis of ischemic stroke. Methods: A total of 98 patients with ischemic stroke were divided into the observation group and the control group according to whether premorbid application of antiplatelet drugs,all the patients were accepted conventional treatment as oxygen,decreasing intracraninal pressure,antiplatelet and so on. NIHSS score,CT brain stroke area on admission,intracranial hemorrhage incidence,symptomatic intracranial hemorrhage incidence,and the death rates at 1 week after therapy were contrasted between the two groups; and the modified Rankin scale was used to evaluate the prognosis of the patients. Results: There was no significantly difference in the NIHSS score or CT brain stroke area before the treatment( P > 0. 05); no significant difference was found in the incidence of intracranial hemorrhage,symptomatic intracranial hemorrhage,and death( P > 0. 05); no significant difference was found in the prognosis( P > 0. 05). Conclusions: Premorbid application of antiplatelet drugs can not cause significant impact on the severity and prognosis of ischemic stroke.

关键词(KeyWords)： 缺血性脑卒中;发病前用药;抗血小板药物;严重程度;预后
ischemic stroke;premorbid application;antiplatelet drug;severity;prognosis

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 赵玉苹
ZHAO Yuping

DOI: 10.19367/j.cnki.1000-2707.2015.02.027

参考文献(References)：

• [1]付娜娜,石正洪.缺血性脑卒中病因分型研究进展[J].中国老年学杂志,2014(12):3489-3491.
• [2]刘捷,司玲珍,张荣申.氯吡格雷与低分子肝素联合治疗短暂性脑缺血发作[J].中国实用医刊,2008(1):89-90.
• [3]卢祖能.2012急性脑卒中溶栓进展回眸[J].卒中与神经疾病,2013(3):封3-封4.
• [4]Hacke W,Kaste M,Bluhmki E,et al.Thrombolysis alteplase 3 to 4.5 hours after acute ischemic stroke[J].N Engl J Med,2008(13):1317-1329.
• [5]Adams HP Jr,del-Zoppo G,Alberts MJ,et al.Fuidelines for the early management of adults with ischemic stroke:a guideline from the American Heart Association/American Stroke Association Stroke Council,Clinical Cardiology Council,Cardiovascular Radiology and Intervention Council,and the Atherosclerosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups:the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists[J].Stroke,2007(5):1655-1711.
• [6]Uyttenboogaart M,Koch MW,Koopman K,et al.Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke[J].Arch Neurol,2008(5):607-611.
• [7]Ibrahim MM,Sebastian J,Hussain M,et al.Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activatormediated recanalization rate in patients with acute ischemic stroke[J].Cerebrovasc Dis,2010(5):508-513.
• [8]Roje-Bedekovi c'M,Vargek-Solter V,Cori c'L,et al.Thrombolysis for acute ischemic stroke-our experiences as part of SITS-MOST[J].Acta Clin Croat,2009(3):287-293.
• [9]Maarten Uyttenboogaart MD.Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke[J].Arch Neurol,2008(5):607-611.
• [10]James C,Grotta MD.Clinical deterioration following improvement in the NINDS rt-PA stroke trial[J].Stroke,2001(32):661-668.
• [11]黄银辉,李明媚,林友榆,等.发病前使用过抗血小板药物对急性缺血性脑卒中患者静脉溶栓疗效的影响[J].第三军医大学学报,2014(3):287-291.

文章评论(Comment)：